Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Shin’ya Takahashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5339-6534; OpenAlex author ID A5003535230, A5110572119. Sources: OpenAlex.

Their work

Papers
33 (first author 0, last author 22)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 4 papers · 2021: 7 papers · 2022: 6 papers · 2023: 4 papers · 2024: 5 papers · 2025: 2 papers · 2026: 1 paper

Papers 33

  1. Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights from a multicenter cohort study in Japan. Co-author DOI 10.1007/s00535-025-02340-x↗
  2. Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ags3.12898↗
  3. A type of pancreatic cancer cells form cell clusters from a solitary condition in a primary ciliogenesis-dependent manner. Co-author DOI 10.1007/s00795-025-00428-0↗
  4. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a ph… Last author DOI 10.1002/jhbp.1412↗
  5. Effects of transmembrane serine protease 4 on the survival in patients with pancreatic ductal adenocarcinoma undergoing surgery followed by adjuvant chemothera… Co-author DOI 10.1007/s00595-024-02824-y↗
  6. Δ3-tubulin impairs mitotic spindle morphology and increases nuclear size in pancreatic cancer cells. Co-author DOI 10.1007/s00795-023-00373-w↗
  7. Effect of body fat mass loss on prognosis of radical resection for pancreatic ductal adenocarcinoma based on bioelectrical impedance analysis. Last author DOI 10.1186/s12893-024-02315-4↗
  8. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-024-15221-z↗
  9. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00423-023-03009-w↗
  10. Prognostic factor in patient with recurrent pancreatic adenocarcinoma. Last author DOI 10.1007/s00423-023-03073-2↗
  11. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutatio… Last author DOI 10.1007/s12328-022-01741-2↗
  12. Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.10.019↗
  13. Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using invers… Last author DOI 10.1002/jhbp.1151↗
  14. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. Last author DOI 10.1007/s00423-021-02339-x↗
  15. Long-term survival after distal pancreatectomy with celiac axis resection and hepatic artery reconstruction in the setting of locally advanced unresectable pan… Last author DOI 10.1007/s12328-022-01621-9↗
  16. Increased clostridium difficile infection in the era of preoperative chemotherapy for pancreatic cancer. Last author DOI 10.1016/j.pan.2021.12.009↗
  17. Impact of disintegrin and metalloproteinase domain-containing protein 12 on pancreatic ductal adenocarcinoma treated with surgical resection and perioperative … Last author DOI 10.1016/j.pan.2022.03.018↗
  18. Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. Last author DOI 10.1016/j.pan.2022.04.004↗
  19. Prognostic significance of dissecting the nerve plexus around the common hepatic artery in pancreatic cancer. Last author DOI 10.1007/s00423-020-02025-4↗
  20. Prognostic Value of Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma Stratified by the Resectability Status. Last author DOI 10.1007/s11605-021-04978-3↗
  21. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial… Last author DOI 10.1016/j.ejca.2021.10.012↗
  22. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Last author DOI 10.1016/j.pan.2021.01.022↗
  23. Identification of Preoperative Risk Factors for Poor Survival in Patients with Resectable Pancreatic Cancer Treated with Upfront Surgery. Last author DOI 10.1159/000520064↗
  24. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-09278-9↗
  25. ASO Author Reflections: Clinical Implications of Circulating Tumor DNA in Pancreatic Cancer Patients. Last author DOI 10.1245/s10434-020-09317-5↗
  26. Reappraisal of the validity of surgery for patients with pancreatic cancer aged 80 years or older stratified by resectability status. Co-author DOI 10.1002/jhbp.687↗
  27. Immunohistological evaluation of mismatch repair deficiency in pancreatic ductal adenocarcinoma treated with surgical resection. Last author DOI 10.1002/jhbp.737↗
  28. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis. Last author DOI 10.1007/s00423-020-01914-y↗
  29. Clinical characteristics of initial recurrence in lung after surgical resection for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2020.08.019↗
  30. Prognostic impact of postoperative complication after pancreatoduodenectomy for pancreatic adenocarcinoma stratified by the resectability status. Co-author DOI 10.1002/jso.25066↗
  31. The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuva… Co-author DOI 10.1016/j.pan.2017.12.014↗
  32. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1007/s00280-017-3274-0↗
  33. Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-016-5120-8↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Uemura · 32 shared papers, 2016–2026 · strength 5.06
  2. Kenjiro Okada · 24 shared papers, 2018–2025 · strength 3.63
  3. Yoshiaki Murakami · 24 shared papers, 2016–2025 · strength 3.32
  4. Tatsuaki Sumiyoshi · 19 shared papers, 2020–2025 · strength 3.05
  5. Naru Kondo · 21 shared papers, 2016–2024 · strength 2.69
  6. Hiroyuki Otsuka · 17 shared papers, 2020–2023 · strength 2.44
  7. Yasutaka Ishii · 8 shared papers, 2021–2026 · strength 1.47
  8. Ryuta Shintakuya · 7 shared papers, 2018–2025 · strength 1.27
  9. Kenta Baba · 5 shared papers, 2023–2025 · strength 1.07
  10. Takumi Harada · 4 shared papers, 2023–2025 · strength 0.84
  11. Takeshi Sudo · 5 shared papers, 2017–2024 · strength 0.81
  12. Yoshiyuki Shibata · 4 shared papers, 2022–2024 · strength 0.73
  13. Atsushi Yamaguchi · 3 shared papers, 2024–2026 · strength 0.64
  14. Koji Ikegami · 2 shared papers, 2024–2025 · strength 0.54
  15. Shiro Oka · 2 shared papers, 2025–2026 · strength 0.49
  16. Shinya Nakamura · 2 shared papers, 2024–2026 · strength 0.44
  17. Taijiro Sueda · 5 shared papers, 2016–2021 · strength 0.43
  18. Tomofumi Tsuboi · 3 shared papers, 2021–2023 · strength 0.43
  19. Sho Tazuma · 2 shared papers, 2024 · strength 0.40
  20. Hirotaka Tashiro · 2 shared papers, 2024 · strength 0.40
  21. Takuro Yamaguchi · 2 shared papers, 2021 · strength 0.35
  22. Eiso Hiyama · 2 shared papers, 2021–2023 · strength 0.32
  23. Takuya Sakoda · 2 shared papers, 2021–2022 · strength 0.29
  24. Kenji SHIRAKAWA · 1 shared paper, 2025 · strength 0.28
  25. Masanobu Yukutake · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.